循環器ジャーナル69巻4号

2021年10月発行

特集 プレシジョン・メディシン時代における腫瘍循環器学の重要性 Ⅲ章　プレシジョン・メディシン時代における循環器系の予防・診断・治療技術

腫瘍循環器領域における治療介入とその評価—ランダム化比較対照試験からリアル・ワールド・エビデンスまで

著者： 田村祐大¹ 田村雄一¹

所属機関： ¹国際医療福祉大学三田病院心臓血管センター

ページ範囲：P.618 - P.625

Point
・がん治療関連心機能障害に対する治療介入における臨床データは着実に増えている．
・腫瘍循環器関連のエビデンスの構築がなされてはいるが，それを上回る速度で悪性腫瘍に対する治療の開発，多様化が進んでいる．
・免疫チェックポイント阻害薬による心筋炎のリアル・ワールド・エビデンスを日本から発信するため，多施設，複数学会の協力の下，データ構築を行っている．

参考文献

1) Hayek SS, Ganatra S, Lenneman C, et al:Preparing the Cardiovascular Workforce to Care for Oncology Patients:JACC Review Topic of the Week. J Am Coll Cardiol 73:2226-2235, 2019

2) Alvarez-Cardona JA, Ray J, Carver J, et al:Cardio-Oncology Leadership Council. Cardio-Oncology Education and Training:JACC Council Perspectives. J Am Coll Cardiol 76:2267-2281, 2020

3) Lenihan DJ, Fradley MG, Dent S, et al:Proceedings from the global Cardio-Oncology summit:the top 10 priorities to actualize for cardiooncology. J Am Coll Cardiol CardioOnc 1:256-272, 2019

4) Cardinale D, Colombo A, Bacchiani G, et al:Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981-1988, 2015

5) Yoon HJ, Kim KH, Kim HY, et al:Impacts of non-recovery of trastuzumab-induced cardiomyopathy on clinical outcomes in patients with breast cancer. Clin Res Cardiol 108:892-900, 2019

6) Macedo AVS, Lyon AR, Nascimento BR, et al:Efficacy of dexrazoxane in preventing anthracycline cardiotoxicityin breast cancer. J Am Coll Cardiol CardioOnc 1:68-79, 2019

7) Cardinale D, Colombo A, Sandri MT, et al:Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474-2481, 2006

8) Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, et al:Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity:The CECCY Trial. J Am Coll Cardiol 71:2281-2290, 2018

9) Kalay N, Basar E, Ozdogru I, et al:Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48:2258-2262, 2006

10) Kaya MG, Ozkan M, Gunebakmaz O, et al:Protective effects of nebivolol against anthracycline-induced cardiomyopathy:a randomized control study. Int J Cardiol 167:2306-2310, 2013

11) Seicean S, Seicean A, Alan N, et al:Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy:follow-up study of heart failure. Circ Heart Fail 6:420-426, 2013

12) Akpek M, Ozdogru I, Sahin O, et al:Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail 17:81-89, 2015

13) Davis MK, Villa D, Tsang TSM, et al:Effect of eplerenone on diastolic function in women receiving anthracycline-based chemotherapy for breast cancer. J Am Coll Cardiol Cardio Onc 2:295-298, 2019

14) Pituskin E, Mackey JR, Koshman S, et al:Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research（MANTICORE 101-Breast）:A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol 35:870-877, 2017

15) Gulati G, Heck SL, Ree AH, et al:Prevention of cardiac dysfunction during adjuvant breast cancer therapy（PRADA）:a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37:1671-1680, 2016

16) Boekhout AH, Gietema JA, Milojkovic Kerklaan B, et al:Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer:A Randomized Clinical Trial. JAMA Oncol 2:1030-1037, 2016

17) Guglin M, Krischer J, Tamura R, et al:Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol 73:2859-2868, 2019

18) Plana JC, Galderisi M, Barac A, et al:Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy:a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27:911-939, 2014

19) Thavendiranathan P, Negishi T, Somerset E, et al:Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. J Am Coll Cardiol 77:392-401, 2021

20) Cardinale D, Ciceri F, Latini R, et al:Anthracycline-induced cardiotoxicity:A multicenter randomised trial comparing two strategies for guiding prevention with enalapril:The International CardioOncology Society-one trial. Eur J Cancer 94:126-137, 2018

21) Abe JI, Yusuf SW, Deswal A, et al:Cardio-Oncology:Learning from the old, applying to the new. Front Cardiovasc Med 7:601893, 2020

22) Salem JE, Manouchehri A, Moey M, et al:Cardiovascular toxicities associated with immune checkpoint inhibitors:an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579-1589, 2018